Photo taken from Manni Mohyuddin/X
Jan 6, 2024, 11:43
Manni Mohyuddin: Carfilzomib is NOT better than bortezomib for newly diagnosed myeloma
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:
“In case this needs to be told again. Carfilzomib is NOT better than bortezomib for newly diagnosed myeloma. It has flunked twice in head-to-head randomized attempts. And observational studies cant answer a question better than two large randomized trials.
References:
- Endurance: KRd versus VRd
- Clarion: KMP versus VMP
I concede to having seen many examples where switching out V for K has led to deepening of responses. But at a population level, it is not better.”
Source: Manni Mohyuddin/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12